Skip to Content
Morningstar

Daiichi Sankyo Co Ltd DSKYF

Morningstar Rating
Unlock
Stock PINX Rating as of
$33.48 −1.42 (4.07%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
DSKYF is trading at a 617% premium.
Price
$33.32
Fair Value
$46.83
Uncertainty
Medium
1-Star Price
$54.41
5-Star Price
$15.52
Economic Moat
Bymq
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DSKYF is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$34.90
Day Range
$33.48–34.98
52-Week Range
$23.45–37.30
Bid/Ask
$31.70 / $36.31
Market Cap
$64.01 Bil
Volume/Avg
1,730 / 5,427

Key Statistics

Price/Earnings (Normalized)
43.76
Price/Sales
5.79
Dividend Yield (Trailing)
0.98%
Dividend Yield (Forward)
1.14%
Total Yield
0.98%

Company Profile

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
18,726
Website
https://www.daiichisankyo.com

Competitors

Valuation

View More
Metric
DSKYF
4519
AZN
Price/Earnings (Normalized)
 43.7625.9821.46
Price/Book Value
 5.764.956.57
Price/Sales
 5.797.855.20
Price/Cash Flow
 35.4324.4624.54
Price/Earnings
DSKYF
4519
AZN

Financial Strength

Metric
DSKYF
4519
AZN
Quick Ratio
 2.324.210.70
Current Ratio
 3.015.530.89
Interest Coverage
 35.14—5.32
Quick Ratio
DSKYF
4519
AZN

Profitability

Metric
DSKYF
4519
AZN
Return on Assets (Normalized)
 6.99%17.64%59.78%
Return on Equity (Normalized)
 12.93%21.05%157.53%
Return on Invested Capital (Normalized)
 10.69%20.98%88.21%
Return on Assets
DSKYF
4519
AZN
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
TzblpzrskSjzhc$841.1 Bil
 Johnson & Johnson
JNJ
HrbrzmqfTszxf$351.3 Bil
 Merck & Co Inc
MRK
CrkgwwrxJmkx$322.9 Bil
 AbbVie Inc
ABBV
HkbdvhpsqWmly$299.6 Bil
 AstraZeneca PLC ADR
AZN
NbfzddnsLkjln$244.3 Bil
 Roche Holding AG ADR
RHHBY
LlsyznkvlkLcgt$222.8 Bil
 Novartis AG ADR
NVS
NzkwnmbgxDcbc$214.2 Bil
 Amgen Inc
AMGN
GrnpnfppjxVqzk$162.7 Bil
 Pfizer Inc
PFE
HslvmvxfTrmyn$152.9 Bil
 Sanofi SA ADR
SNY
LldhhjhWkpf$117.4 Bil

Sponsor Center